Sponsor Pulls Plug on Trials of Add-On AMD Treatment

by Medscape • 2025/04/03 • 0 Comments

An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 trials, so the sponsor halted both trials.
Medscape Medical News

← Vitrectomy offers relief for vitreous opacities

Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease →

Post navigation